Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 3,047 shares at $14.25 ($44K) on 2020-07-07, disclosed to the SEC on 2020-07-09.
Scheduled sale ($44k) by CEO and President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.25 | 754 | $11K | 24.7% |
| 2 | $14.31 | 2,293 | $33K | 75.3% |
| Total | $14.30 avg | 3,047 | $44K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |